专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20160152671A1 CHLOROTOXIN POLYPEPTIDES AND CONJUGATES AND USES THEREOF 有权
公开(公告)号：US20160152671A1
公开(公告)日：2016-06-02
申请号：US14956261
申请日：2015-12-01
申请人： MORPHOTEK, INC.
发明人： Abdellah SENTISSI , Douglas B. JACOBY
IPC分类号： C07K14/435 , A61K31/7068 , A61K31/337 , A61K47/48 , G01N33/574
CPC分类号： C07K14/43522 , A61K31/337 , A61K31/7068 , A61K38/00 , A61K47/48215 , A61K47/48261 , A61K47/60 , A61K47/6415 , A61K51/088 , G01N33/57415 , G01N33/57434
摘要： Reduced lysine chlorotoxin polypeptides that may be used to generate single species conjugates of chlorotoxin. Conjugates comprising such chlorotoxin polypeptides and pharmaceutical compositions thereof. Methods of using such compositions and/or conjugates.

2. 发明申请

US20160058885A1 Antibodies With Immune Effector Activity and that Internalize In Folate Receptor Alpha-positive Cells 审中-公开
标题翻译：具有免疫效应活性的抗体，并且在叶酸受体α阳性细胞内部化
公开(公告)号：US20160058885A1
公开(公告)日：2016-03-03
申请号：US14809887
申请日：2015-07-27
申请人： Morphotek, Inc.
发明人： Luigi Grasso , Nicholas C. Nicolaides , Philip M. Sass
IPC分类号： A61K47/48 , C07K16/30 , A61K31/704
CPC分类号： C07K16/30 , A61K31/704 , A61K31/7068 , A61K39/39558 , A61K47/6825 , A61K47/6851 , A61K47/6869 , A61K47/6897 , B82Y5/00 , C07K16/22 , C07K16/28 , C07K16/3069 , C07K2317/21 , C07K2317/24 , C07K2317/732 , C07K2317/76 , C07K2317/77
摘要： This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing folate receptor alpha (FRA) and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to FRA-expressing cells as well as in eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer cells; and methods of treating cancer using the antibodies.
摘要翻译：本发明涉及单克隆抗体和多克隆抗体的用途，其特异性结合并具有替代性的能力，其被表达叶酸受体α（FRA）的细胞内化，并诱导免疫效应物活性如抗体依赖性细胞毒性。所述抗体可用于特异性递送表达FRA的细胞的药理学物质，以及引发特异性的肿瘤细胞和前体的免疫效应物活性。本发明还涉及编码本发明抗体的核苷酸，表达抗体的细胞; 检测癌细胞的方法; 以及使用抗体治疗癌症的方法。

3. 发明申请

US20150374860A1 TREATMENT OF METASTATIC TUMORS 有权
公开(公告)号：US20150374860A1
公开(公告)日：2015-12-31
申请号：US14702934
申请日：2015-05-04
申请人： MORPHOTEK, INC.
发明人： Alison O'Neill , Douglas B. Jacoby , Abdellah Sentissi , Kamala Kesavan , E. Michael Egan , Laura Sen
IPC分类号： A61K51/08 , A61K45/06 , C12N15/113 , A61K38/17 , A61K47/48
CPC分类号： A61K51/08 , A61K38/164 , A61K38/1767 , A61K45/06 , A61K47/60 , A61K47/6415 , C07K2319/33 , C07K2319/55 , C12N15/111 , C12N15/113 , C12N2310/11 , C12N2310/14 , C12N2310/351 , C12N2310/3513 , C12N2320/31 , C12N2320/32
摘要： The present invention is directed to methods and methods for the treatment, inhibition and/or reduction, and detection of metastatic tumors. In some embodiments, the inventive methods include systemic (e.g., intravenous) administration of a chlorotoxin agent that may or may not be labeled. In some embodiments, the inventive methods allow treatment, inhibition and/or reduction, and detection of metastases in the brain. In some embodiments, neovascularization is inhibited and/or newly formed vessels are caused to regress.

4. 发明申请

US20150079104A1 Methods For Inhibiting The Binding Of Endosialin To Ligands 有权
标题翻译：抑制唾液酸对配体结合的方法
公开(公告)号：US20150079104A1
公开(公告)日：2015-03-19
申请号：US14509353
申请日：2014-10-08
申请人： Morphotek, Inc.
发明人： Yuhong Zhou , Brian Tomkowicz , Luigi Grasso , Nicholas C. Nicolaides , Philip M. Sass
IPC分类号： C07K16/28
CPC分类号： C07K16/2851 , A61K47/6803 , A61K47/6849 , A61K2039/505 , C07K2317/14 , C07K2317/24 , C07K2317/56 , C07K2317/76 , C07K2319/30
摘要： The invention provides methods for inhibiting the interaction of endosialin with endosialin ligands. The inhibition is effectuated on the genetic level, by inhibiting endosialin gene expression, and on the protein level, by blocking the interaction of cell-surface expressed endosialin with ligands such as fibronectin and collagen. The invention provides methods for identifying inhibitors of the interaction of endosialin with endosialin ligands. Also provided are methods for inhibiting angiogenesis and neovascularization in vivo and in vitro.
摘要翻译：本发明提供了抑制内皮素与内皮素配体相互作用的方法。通过抑制内皮素基因表达和蛋白质水平，通过阻断细胞表面表达的内皮唾液酸与诸如纤连蛋白和胶原的配体的相互作用来实现抑制。本发明提供鉴定抑制剂的方法，所述抑制剂与内皮素配体相关。还提供了用于在体内和体外抑制血管生成和新生血管形成的方法。

5. 发明申请

US20150030537A1 CHLOROTOXIN POLYPEPTIDES AND CONJUGATES AND USES THEREOF 有权
标题翻译：氯霉素多糖及其结合物及其用途
公开(公告)号：US20150030537A1
公开(公告)日：2015-01-29
申请号：US14450182
申请日：2014-08-01
申请人： MORPHOTEK, INC.
发明人： Abdellah Sentissi , Douglas B. Jacoby
IPC分类号： C07K14/435 , A61K47/48 , A61K31/337 , A61K51/08
CPC分类号： C07K14/43522 , A61K31/337 , A61K31/7068 , A61K38/00 , A61K47/48215 , A61K47/48261 , A61K47/60 , A61K47/6415 , A61K51/088 , G01N33/57415 , G01N33/57434
摘要： Reduced lysine chlorotoxin polypeptides that may be used to generate single species conjugates of chlorotoxin. Conjugates comprising such chlorotoxin polypeptides and pharmaceutical compositions thereof. Methods of using such compositions and/or conjugates.
摘要翻译：降低赖氨酸氯毒素多肽，其可用于产生氯毒素的单物质共轭物。包含这种氯毒素多肽的缀合物及其药物组合物。使用这种组合物和/或共轭物的方法。

6. 发明授权

US08658173B2 Anti-mesothelin antibodies 有权
标题翻译：抗间皮素抗体
公开(公告)号：US08658173B2
公开(公告)日：2014-02-25
申请号：US13799766
申请日：2013-03-13
申请人： Morphotek, Inc.
发明人： Wolfgang Ebel , Luigi Grasso , Nicholas C. Nicolaides , Philip M. Sass , Eric Routhier
IPC分类号： A61K39/395
CPC分类号： C07K16/28 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/30 , C07K16/3069 , C07K2317/56 , C07K2317/732 , C07K2317/77
摘要： This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and become internalized by mesothelin-positive cells and also induce an immune effector activity such as antibody dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to mesothelin expressing cells as well as eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to cells expressing the monoclonal antibodies, polyclonal antibodies, antibody derivatives, such as human, humanized, and chimeric monoclonal antibodies, antibody fragments, mammalian cells expressing the monoclonal antibodies, derivatives and fragments, and methods of treating cancer using the antibodies, derivatives and fragments.
摘要翻译：本发明涉及单克隆和多克隆抗体的使用，其特异性结合并被间皮素阳性细胞内化，并且还诱导免疫效应子活性如抗体依赖性细胞毒性。该抗体可用于特异性递送表达间皮素的药物学药剂，以及引发免疫效应物特异性对肿瘤细胞和前体的活性。本发明还涉及表达单克隆抗体，多克隆抗体，抗体衍生物如人，人源化和嵌合单克隆抗体的细胞，抗体片段，表达单克隆抗体的哺乳动物细胞，衍生物和片段，以及使用抗体，衍生物和片段。

7. 发明申请

US20130177571A1 Anti-Mesothelin Antibodies 有权
公开(公告)号：US20130177571A1
公开(公告)日：2013-07-11
申请号：US13799766
申请日：2013-03-13
申请人： Morphotek, Inc.
发明人： Wolfgang Ebel , Luigi Grasso , Nicholas C. Nicolaides , Philip M. Sass , Eric Routhier
IPC分类号： C07K16/28 , A61K45/06 , A61K39/395
CPC分类号： C07K16/28 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/30 , C07K16/3069 , C07K2317/56 , C07K2317/732 , C07K2317/77
摘要： This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and become internalized by mesothelin-positive cells and also induce an immune effector activity such as antibody dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to mesothelin expressing cells as well as eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to cells expressing the monoclonal antibodies, polyclonal antibodies, antibody derivatives, such as human, humanized, and chimeric monoclonal antibodies, antibody fragments, mammalian cells expressing the monoclonal antibodies, derivatives and fragments, and methods of treating cancer using the antibodies, derivatives and fragments.

8. 发明授权

US10183975B2 Chlorotoxin polypeptides and conjugates and uses thereof 有权
公开(公告)号：US10183975B2
公开(公告)日：2019-01-22
申请号：US15468085
申请日：2017-03-23
申请人： MORPHOTEK, INC.
发明人： Abdellah Sentissi , Douglas B. Jacoby
IPC分类号： A61K38/00 , A61K47/48 , C07K14/435 , A61P35/00 , A61K31/337 , A61K51/08 , A61K31/7068 , G01N33/574 , A61K47/60 , A61K47/64
摘要： Reduced lysine chlorotoxin polypeptides that may be used to generate single species conjugates of chlorotoxin. Conjugates comprising such chlorotoxin polypeptides and pharmaceutical compositions thereof. Methods of using such compositions and/or conjugates.

9. 发明授权

US09603952B2 Treatment of metastatic tumors 有权
公开(公告)号：US09603952B2
公开(公告)日：2017-03-28
申请号：US14702934
申请日：2015-05-04
申请人： MORPHOTEK, INC.
发明人： Alison O'Neill , Douglas B. Jacoby , Abdellah Sentissi , Kamala Kesavan , E. Michael Egan
IPC分类号： C07H21/02 , C07H21/04 , A61K51/08 , A61K45/06 , A61K47/48 , A61K38/16 , C12N15/11 , A61K38/17 , C12N15/113
CPC分类号： A61K51/08 , A61K38/164 , A61K38/1767 , A61K45/06 , A61K47/60 , A61K47/6415 , C07K2319/33 , C07K2319/55 , C12N15/111 , C12N15/113 , C12N2310/11 , C12N2310/14 , C12N2310/351 , C12N2310/3513 , C12N2320/31 , C12N2320/32
摘要： The present invention is directed to methods and methods for the treatment, inhibition and/or reduction, and detection of metastatic tumors. In some embodiments, the inventive methods include systemic (e.g., intravenous) administration of a chlorotoxin agent that may or may not be labeled. In some embodiments, the inventive methods allow treatment, inhibition and/or reduction, and detection of metastases in the brain. In some embodiments, neovascularization is inhibited and/or newly formed vessels are caused to regress.

10. 发明授权

US09522195B2 Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells 有权
公开(公告)号：US09522195B2
公开(公告)日：2016-12-20
申请号：US14809887
申请日：2015-07-27
申请人： Morphotek, Inc.
发明人： Luigi Grasso , Nicholas C. Nicolaides , Philip M. Sass
IPC分类号： C07K16/28 , C07K16/30 , A61K47/48 , B82Y5/00 , A61K31/704
CPC分类号： C07K16/30 , A61K31/704 , A61K31/7068 , A61K39/39558 , A61K47/6825 , A61K47/6851 , A61K47/6869 , A61K47/6897 , B82Y5/00 , C07K16/22 , C07K16/28 , C07K16/3069 , C07K2317/21 , C07K2317/24 , C07K2317/732 , C07K2317/76 , C07K2317/77
摘要： This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing folate receptor alpha (FRA) and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to FRA-expressing cells as well as in eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer cells; and methods of treating cancer using the antibodies.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式